Open AccessAbstract CT024: Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC)
Author(s) -
Karthick Vishwanathan,
James Dunyak,
Philip Overend,
Ryan J. Hartmaier,
Aleksandra Markovets,
Juliann Chmielecki,
Ganesh Mugundu,
Carl Barrett,
Helen Tomkinson,
Martin Johnson
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct024
Subject(s) - osimertinib , gefitinib , medicine , erlotinib , oncology , hazard ratio , proportional hazards model , epidermal growth factor receptor , lung cancer , progression free survival , tyrosine kinase inhibitor , response evaluation criteria in solid tumors , clinical trial , cancer , confidence interval , phases of clinical research , chemotherapy